| Name | Title | Contact Details |
|---|---|---|
David Glosser |
Associate Director, Information Security | Profile |
Adrian Rodriguez |
Director, Information Security, IT Portfolio Management | Profile |
Axovant Sciences is a leading clinical-stage neurology company focused on the treatment of dementia and related neurological disorders. We aspire to lead the way into a new era of progress to protect the fullness of life for people living with neurologic conditions. We see the potential of compelling therapeutic pathways and set our sights high on creating life-changing advancement for millions of people affected by neurologic disorders.
Vera Whole Health is a market-leading healthcare service that delivers comprehensive, intelligent primary care to employees via employer-funded worksite clinics. At the core of our philosophy is the belief that behavior change is the only sustainable way to help people live healthier. And we’ve found through experience and research that a person’s peer group is the primary motivator to that behavior change. That is why Vera Whole Health, in addition to offering primary care and health coaching to individuals, invests time and resources into helping companies change their health culture.
Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Our proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Our initial focus is to advance RCT™ product candidates for the treatment cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. We are currently enrolling patients in a Phase 1/2 clinical trial of RTX-240; the trial has two Phase 1 arms enrolling adult patients with advanced solid tumors: an ongoing monotherapy dose escalation arm in adults with relapsed/refractory or locally advanced solid tumors and a combination therapy dose escalation arm with pembrolizumab in adults with relapsed/refractory or locally advanced solid tumors. In April 2022, the combination arm with pembrolizumab was expanded to focus on non-small cell lung cancer and renal cell carcinoma patients. We are also enrolling patients in a Phase 1/2 clinical trial of RTX-224 for the treatment of patients with certain advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelial (bladder) carcinoma and triple-negative breast cancer.
Homology is based on groundbreaking science that harnesses the naturally occurring process of homologous recombination. This non-nuclease-based approach offers clear advantages in its precision, efficiency and on-target in vivo editing of genetic mutations. Homology obtained an exclusive worldwide license to this technology platform, which is based on the pioneering research of Saswati Chatterjee, Ph.D., Professor of Virology at the Beckman Research Institute at the City of Hope in California, member of the Recombinant DNA Advisory Committee (RAC) to the Office of the Director, National Institutes of Health (NIH) and former charter member of the Therapeutic Approaches to Genetic Diseases Study Section of the NIH. Dr. Chatterjee and her team led the first adeno-associated virus (AAV) vector-mediated gene transfer studies into human hematopoietic stem cells and subsequently identified and isolated a series of naturally-occurring AAVs from human CD34+ cells.
BioIntervene, Inc. is a preclinical-stage biopharmaceutical company committed to the discovery and development of effective and non-addictive medicines for chronic pain and other chronic inflammatory and neurodegenerative disorders. The Company was founded in 2014 based on insights from research at Saint Louis University and the National Institutes of Health (NIH). BioIntervene`s founding team has pioneered the understanding of adenosine A3 receptor biology, with a focus on developing first-in-class, selective adenosine A3 receptor agonists. California, United States Read more at CB Insights: https://www.cbinsights.com/company/biointervene